RET, ROS1 and ALK fusions in lung cancer | Zendy

Kengo Takeuchi | Zendy; Manabu Soda | Zendy; Yosuke Togashi | Zendy; Ritsuro Suzuki | Zendy; Seiji Sakata | Zendy; Satoko Hatano | Zendy; Reimi Asaka | Zendy; Wakako Hamanaka | Zendy; Hironori Ninomiya | Zendy; Hirofumi Uehara | Zendy; Young Lim Choi | Zendy; Yukitoshi Satoh | Zendy; Sakae Okumura | Zendy; Ken Nakagawa | Zendy; Hiroyuki Mano | Zendy; Yuichi Ishikawa | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

RET, ROS1 and ALK fusions in lung cancer

Author(s) -

Kengo Takeuchi,

Manabu Soda,

Yosuke Togashi,

Ritsuro Suzuki,

Seiji Sakata,

Satoko Hatano,

Reimi Asaka,

Wakako Hamanaka,

Hironori Ninomiya,

Hirofumi Uehara,

Young Lim Choi,

Yukitoshi Satoh,

Sakae Okumura,

Ken Nakagawa,

Hiroyuki Mano,

Yuichi Ishikawa

Publication year - 2012

Publication title -

nature medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.536

H-Index - 547

eISSN - 1546-170X

pISSN - 1078-8956

DOI - 10.1038/nm.2658

Subject(s) - ros1 , anaplastic lymphoma kinase , cancer research , adenocarcinoma , oncogene , lung cancer , receptor tyrosine kinase , tyrosine kinase , fusion gene , cancer , kinase , viral oncogene , targeted therapy , crizotinib , biology , medicine , oncology , receptor , gene , genetics , cell cycle , malignant pleural effusion

Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for ROS1. In addition, we discovered previously unidentified kinase fusions that may be promising for molecular-targeted therapy, kinesin family member 5B (KIF5B)-ret proto-oncogene (RET) and coiled-coil domain containing 6 (CCDC6)-RET, in 14 adenocarcinomas. A multivariate analysis of 1,116 adenocarcinomas containing these 71 kinase-fusion-positive adenocarcinomas identified four independent factors that are indicators of poor prognosis: age ≥ 50 years, male sex, high pathological stage and negative kinase-fusion status.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research